RioDerm-002 is under clinical development by Rion and currently in Phase I for Radiation Injury. According to GlobalData, Phase I drugs for Radiation Injury does not have sufficient historical data to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback